https://www.selleckchem.com/products/SGX-523.html
The increasing financial burden associated with diabetes treatment presents a challenge to healthcare systems worldwide. Recently, clinical guidelines have focussed on patients with type2 diabetes (T2D) and established cardiovascular disease (CVD) and recommend a sodium-glucose co-transporter2 (SGLT2) inhibitor or a glucagon-like peptide1 (GLP-1) receptor agonist as second-line treatment after metformin or independently of baseline glycated haemogloblin A1c (HbA1c). In Danish clinical guidelines, empagliflozin and liraglutide are highli
Like
Comment
Share
